Business & Finance Pharma major Novartis falls 9% after three drug trial setbacks
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
By
· September 8, 2026 · 1 min read
This article was originally published by
CNBC Top News
and is republished here under license.
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
Related
EverBank has agreed to acquire WaFd, a smaller bank in the Pacific Northwest, in a $3.9 billion reverse merger transaction,…
By
· September 8, 2026 · 1 min read
The Department of Energy has given grants to small battery tech companies. But the U.S. has a few years to…
By
· September 8, 2026 · 1 min read
The bank upgraded Lockheed Martin to buy from neutral.…
By
· September 8, 2026 · 1 min read
Leave a Reply